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611Abstracts
grafts, angioplasty, haemodialysis and diabetes were
“lumped” together for analysis. We re-evaluated the data
by meta-analysing sub-groups of trials according to the
risk factor of the patient population (where there was
more than one trial for the risk factor). RESULTS: The
Relative Risk Reductions with [95% CI] for DP + ASA
compared to ASA alone for all types of patients was cal-
culated to be 5% [-5 to 15%]. However the RRRs were
diverse when trial patient populations were split for
analysis. RRRs ranged from 15% [4% to 26%] for
patients with previous Stroke/TIA to -19% [-62% to
12%] for patients who had had CABG previous to enter-
ing the study. CONCLUSIONS: The usefulness of the
ATC’s summary statistics in decision-making for speciﬁc
patient populations is limited, due to heterogeneous
patient populations being combined together. In particu-
lar, our sub-group analysis revealed a statistically signiﬁ-
cant RRR in vascular events for patients treated with DP
+ ASA compared to ASA amongst patients with previous
TIA/stroke.
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OBJECTIVE: Various representations of uncertainty in
cost effectiveness analysis alongside a randomized trial
have been suggested. Due to its informational richness the
cost acceptability curve has been favored. Alternative rep-
resentations of uncertainty are conﬁdence intervals and
bootstrap distribution in the c/e plane. If the difference in
effects is small different problems arise with either of the
methods. Aspects of using the different presentations of
uncertainty for decision making are discussed for the
study example. METHODS: Methods compared included
cost-effectiveness acceptability curve bootstrap conﬁ-
dence intervals and bootstrap scatter plots focusing on
their user-friendliness, informational richness and guid-
ance for decision making. Data came from an economic
evaluation in the rehabilitation of low back patients that
has been performed in two German rehabilitation centers.
Treatment in the standard arm consisted of a multimodal
program including physiotherapy and educational mea-
sures. The experimental group received additional psy-
chological treatment. RESULTS: The cost effectiveness
acceptability curve intersecting at 0.61 showed a small
slope. The bootstrap conﬁdence interval ranged from €1.4
million to €-20.000 covering points in all quadrants.
61% of the bootstrap replicates where in the southeast
quadrant indicating dominance. CONCLUSIONS: Sug-
gestions are made for further discussion of using uncer-
tain results for decision making as a conservative rule for
a risk-neutral decision maker, it is suggested that a 50%
probability of the intervention being dominant (as found
in the study) may not be used to reject it on economic
grounds.
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OBJECTIVE: Assessment of patient preferences for
attributes of asthma treatments. METHODS: Two
hundred ninety-eight patients, aged 18–60, from 15
centres in Sweden completed a questionnaire concern-
ing their asthma and ranked 18 alternative treatments
using conjoint analysis. Patients were treated with either
inhaled corticosteroids (ICS) or short acting bron-
chodilator alone (n = 123) or ICS and long acting bron-
chodilator (separate inhalers n = 87, combination inhaler
n = 88). Attributes analysed were: maintenance treatment,
additional reliever, time to onset and duration of reliever,
number of symptom-free days (SFD) per month, and out-
of-pocket cost per month. RESULTS: Conjoint analysis
showed that the most important aspect of treatment was
SFD. Forty percent of the patients had 15 or less SFD per
month. Eighty-ﬁve percent of the patients preferred
another treatment than their current treatment. Treat-
ment preferences were heterogeneous and in 78% not
covered by current treatment guidelines. One of two
patients preferred a combination inhaler to separate
inhalers, and three of four patients a reliever that is both
rapid- and long-acting. The most preferred treatment was
a combination inhaler for maintenance and reliever use.
On average, the patients were willing to pay SEK 328
(USD $36), additionally to their current expenditure, per
month for the change to the preferred treatment. CON-
CLUSION: Symptom-free days were the most important
attribute in asthma treatment. Patients were willing to
pay for a switch to their preferred treatment. The most
favoured treatments were a reliever therapy that is both
rapid- and long acting and a combination inhaler for both
maintenance and as needed use.
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